Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas

Waldemar Debinski, Denise M. Gibo, Stanley W. Hulet, James Connor, G. Yancey Gillespie

Research output: Contribution to journalArticle

168 Citations (Scopus)

Abstract

Glioblastoma multiforme (GBM) is an incurable brain tumor. Due to the striking heterogeneity that characterizes GBM, there is no known tumor- specific antigen or receptor that is expressed by a majority of GBM patients. We found that virtually all studied human GBM specimens (23 samples) abundantly expressed a receptor for interleukin (IL)-13 in situ, whereas normal human brain had few, if any, IL-13-binding sites. The GBM-associated IL-13 receptor was both quantitatively and qualitatively different from and, thus, more restrictive than the shared signaling receptor of normal tissue: it was IL-4 independent. The receptor for IL-13 was overexpressed by a majority of cancer cells in situ. Furthermore, cytotoxins targeted to this more restrictive IL-13R produced cures in animals bearing xenografts of human high-grade gliomas. Thus, unexpectedly, the receptor for an immune regulatory cytokine may be a long sought marker and, concomitantly, a unique imaging site and therapeutic target for GBM, the most malignant and the most heterogeneous of brain tumors.

Original languageEnglish (US)
Pages (from-to)985-990
Number of pages6
JournalClinical Cancer Research
Volume5
Issue number5
StatePublished - May 1999

Fingerprint

Interleukin-13 Receptors
Glioblastoma
Glioma
Brain Neoplasms
Therapeutics
Antigen Receptors
Interleukin-13
Interleukins
Cytotoxins
Neoplasm Antigens
Heterografts
Interleukin-4
Binding Sites
Cytokines
Brain

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

Debinski, W., Gibo, D. M., Hulet, S. W., Connor, J., & Gillespie, G. Y. (1999). Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clinical Cancer Research, 5(5), 985-990.
Debinski, Waldemar ; Gibo, Denise M. ; Hulet, Stanley W. ; Connor, James ; Gillespie, G. Yancey. / Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. In: Clinical Cancer Research. 1999 ; Vol. 5, No. 5. pp. 985-990.
@article{f7519cbbd5cc4389a0d5387428602ec4,
title = "Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas",
abstract = "Glioblastoma multiforme (GBM) is an incurable brain tumor. Due to the striking heterogeneity that characterizes GBM, there is no known tumor- specific antigen or receptor that is expressed by a majority of GBM patients. We found that virtually all studied human GBM specimens (23 samples) abundantly expressed a receptor for interleukin (IL)-13 in situ, whereas normal human brain had few, if any, IL-13-binding sites. The GBM-associated IL-13 receptor was both quantitatively and qualitatively different from and, thus, more restrictive than the shared signaling receptor of normal tissue: it was IL-4 independent. The receptor for IL-13 was overexpressed by a majority of cancer cells in situ. Furthermore, cytotoxins targeted to this more restrictive IL-13R produced cures in animals bearing xenografts of human high-grade gliomas. Thus, unexpectedly, the receptor for an immune regulatory cytokine may be a long sought marker and, concomitantly, a unique imaging site and therapeutic target for GBM, the most malignant and the most heterogeneous of brain tumors.",
author = "Waldemar Debinski and Gibo, {Denise M.} and Hulet, {Stanley W.} and James Connor and Gillespie, {G. Yancey}",
year = "1999",
month = "5",
language = "English (US)",
volume = "5",
pages = "985--990",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

Debinski, W, Gibo, DM, Hulet, SW, Connor, J & Gillespie, GY 1999, 'Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas', Clinical Cancer Research, vol. 5, no. 5, pp. 985-990.

Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. / Debinski, Waldemar; Gibo, Denise M.; Hulet, Stanley W.; Connor, James; Gillespie, G. Yancey.

In: Clinical Cancer Research, Vol. 5, No. 5, 05.1999, p. 985-990.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas

AU - Debinski, Waldemar

AU - Gibo, Denise M.

AU - Hulet, Stanley W.

AU - Connor, James

AU - Gillespie, G. Yancey

PY - 1999/5

Y1 - 1999/5

N2 - Glioblastoma multiforme (GBM) is an incurable brain tumor. Due to the striking heterogeneity that characterizes GBM, there is no known tumor- specific antigen or receptor that is expressed by a majority of GBM patients. We found that virtually all studied human GBM specimens (23 samples) abundantly expressed a receptor for interleukin (IL)-13 in situ, whereas normal human brain had few, if any, IL-13-binding sites. The GBM-associated IL-13 receptor was both quantitatively and qualitatively different from and, thus, more restrictive than the shared signaling receptor of normal tissue: it was IL-4 independent. The receptor for IL-13 was overexpressed by a majority of cancer cells in situ. Furthermore, cytotoxins targeted to this more restrictive IL-13R produced cures in animals bearing xenografts of human high-grade gliomas. Thus, unexpectedly, the receptor for an immune regulatory cytokine may be a long sought marker and, concomitantly, a unique imaging site and therapeutic target for GBM, the most malignant and the most heterogeneous of brain tumors.

AB - Glioblastoma multiforme (GBM) is an incurable brain tumor. Due to the striking heterogeneity that characterizes GBM, there is no known tumor- specific antigen or receptor that is expressed by a majority of GBM patients. We found that virtually all studied human GBM specimens (23 samples) abundantly expressed a receptor for interleukin (IL)-13 in situ, whereas normal human brain had few, if any, IL-13-binding sites. The GBM-associated IL-13 receptor was both quantitatively and qualitatively different from and, thus, more restrictive than the shared signaling receptor of normal tissue: it was IL-4 independent. The receptor for IL-13 was overexpressed by a majority of cancer cells in situ. Furthermore, cytotoxins targeted to this more restrictive IL-13R produced cures in animals bearing xenografts of human high-grade gliomas. Thus, unexpectedly, the receptor for an immune regulatory cytokine may be a long sought marker and, concomitantly, a unique imaging site and therapeutic target for GBM, the most malignant and the most heterogeneous of brain tumors.

UR - http://www.scopus.com/inward/record.url?scp=0032901749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032901749&partnerID=8YFLogxK

M3 - Article

C2 - 10353730

AN - SCOPUS:0032901749

VL - 5

SP - 985

EP - 990

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 5

ER -